Product pipeline

• + Acromegaly - Octreotide
• + Prostate cancer - PCK3145
• + Prostate cancer - Goserelin
• + Cancer - NGR-Delivery Technology
• + HIV/AIDS - Protease Inhibitors
• + HIV/AIDS - Integrase Inhibitors
• + HIV/AIDS - Entry Inhibitors
• + HCV - Polymerase Inhibitors
• + HCV - Entry Inhibitors
• + Influenza A - M2 Proton Channel Inhibitors
• + Diagnostic - PSP94
• + Diagnostic - Colopath® / ColorectAlert™

Prostate cancer - PCK3145

Scientific references

Articles

• Annabi, B., et al. Inhibition of MMP-9 secretion by the anti-metastatic PSP94 derived peptide PCK3145 requires cell surface laminin receptor signaling. Anti-Cancer Drugs 2006, Vol. 17, pp 429-438.
• Lamy, S., et al. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signaling in endothelial cells: implication in tumor angiogenesis. Int. J. Cancer 2006, Vol. 118, pp 2350-2358.
• Annabi, B., et al. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: Implications in tumor metastasis. Clinical & Experimental Metastasis 2005, Vol. 22, pp 429-439.
• Hawkins, R.E., et al. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clinical Prostate Cancer 2005, Vol. 4, pp 91-99.
• Shukeir, N., et al. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Research 2004, Vol. 64, pp 5370-5377.
• Shukeir, N., et al. Prostate secretory protein PSP94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Research 2003, Vol. 63 pp 2072-2078.
• Garde, S., et al. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cell line (PC3) and xenografts by inducing apoptosis. The Prostate 1999, Vol. 38, pp 118-125.

Presentations

• Guérin, M., et al. Synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein with in vitro and in vivo activity against non-Hodgkins lymphoma and other hematologic malignancies. ASH 49th Annual Meeting - Atlanta, Georgia, USA, December 8-11, 2007.
• Slovin, S., et al. PCK3145 - A Novel Multitargeted Signaling Agent for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) AACR-NCI-EORTC International Conference - San Francisco, California, U.S.A., October 22-26, 2007.
• Dulude, H., et al. PCK3145 administered weekly reduces the plasma MMP-9 level in metastatic Hormone Refractory Prostate Cancer (HRPC) patients. ASCO Prostate Cancer - San Francisco, California, U.S.A., February 2006.
• Slovin, S., et al. Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC) – the US experience. ASCO Prostate Cancer - San Francisco, California, U.S.A., February 2006.
• Panchal, C. PCK3145, a novel signal transduction inhibitor for treating late stage prostate cancer. 3rd Angiogenesis Foundation’s Annual Symposium - Boston, Massachusetts, U.S.A., October 2005
• Wu, J., et al. Inhibition of multiple signaling pathways by PCK3145 and its implication in the treatment of prostate cancer. Prostate Cancer Foundation - Scotsdale, Arizona, U.S.A., September 2005.
• Daigneault, L., et al. A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer. ASCO - Orlando, Florida, U.S.A., May 2005.
• Lamy, S., et al. A prostate secretory protein 94 (PSP94)-derived synthetic peptide (PCK3145) antagonizes VEGF signaling in endothelial cells: Implications in tumor angiogenesis. AACR - Anaheim, California, U.S.A., April 2005.
• Garde, S., et al. Inhibition of angiogenesis and MMP-9 production by a synthetic peptide (PCK3145) in a syngeneic model of rat prostate cancer results in decreased tumor growth and skeletal metastasis in-vitro and in-vivo. AACR - Anaheim, California, U.S.A., April 2005.
• Daigneault, L., et al. A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer. ASCO Prostate Cancer - Orlando, Florida, U.S.A., February 2005.
• Lemoyne, C., et al. Determination of PCK3145 (peptide) in human plasma by LC/MS/MS. AAPS - Baltimore, Maryland, U.S.A., November 2004.
• Panchal, C., et al. Development of a novel peptide drug PCK3145 derived from the naturally occurring prostate secretory protein PSP94. INCP - Zermatt, Switzerland, November 2004.
• Panchal, C., et al. Clinical development of a synthetic peptide, PCK3145, for treatment of Hormone Refractory Prostate Cancer patients. Prostate Cancer Foundation - Lake Tahoe, Nevada, U.S.A., October 2004
• Daigneault, L., et al. Evaluation of biological activity of PCK3145 in metastatic hormone resistant prostate cancer (HRPC) using serum markers. ASCO - New Orleans, Louisiana, U.S.A., June 2004.
• Hawkins, R., et al. A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145 administered intravenously in patients with metastatic hormone refractory prostate cancer (HRPC). ASCO - New Orleans, Louisiana, U.S.A., June 2004.
• Dulude, H., et al. Safety, tolerability, pharmacokinetic and escalating single doses of PCK3145 in patients with metastatic hormone resistant prostatic cancer (HRPC). AACR - Orlando, Florida, U.S.A., March 2004.
• Panchal, C., et al. Development of a synthetic peptide, PCK3145, for human clinical trials involving HRPC patients. CapCure, New York, New York, U.S.A., November 2003.
• Shukeir, N., et al. A synthetic 15 mer peptide derived from prostate secretory protein (PSP94) can reduce tumor growth, skeletal metastases and malignancy associated hypercalcemia. AACR - Washington, District of Columbia, U.S.A. June 2003.